Yarrow Bioscience (NASDAQ:YARW) versus ADC Therapeutics (NYSE:ADCT) Head to Head Contrast

Yarrow Bioscience (NASDAQ:YARW) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Yarrow Bioscience and ADC Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
ADC Therapeutics	-121.77%	N/A	-32.74%

Analyst Recommendations

This is a summary of recent recommendations for Yarrow Bioscience and ADC Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1	0	2	0	2.33
ADC Therapeutics	1	2	3	0	2.33

Yarrow Bioscience presently has a consensus target price of $58.00, indicating a potential upside of 191.46%. ADC Therapeutics has a consensus target price of $5.00, indicating a potential upside of 227.87%. Given ADC Therapeutics’ higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Yarrow Bioscience.

Volatility and Risk

Yarrow Bioscience has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.

Institutional & Insider Ownership

83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by company insiders. Comparatively, 5.1% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Yarrow Bioscience and ADC Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570,000.00	93.22	-$26.48 million	($14.64)	-1.36
ADC Therapeutics	$81.36 million	2.39	-$142.62 million	($0.66)	-2.31

Yarrow Bioscience has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

ADC Therapeutics beats Yarrow Bioscience on 8 of the 13 factors compared between the two stocks.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.